Network origin in Günter Wellnhofer first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
63
| Public Company | Biotechnology | 63 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Günter Wellnhofer via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Investor Relations Contact | |
| IMMUNOGEN, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| QIAGEN N.V. | Medical Specialties | Founder Public Communications Contact | |
| BAYER AG | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| ILLUMINA, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SANOFI | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| 4SC AG | Biotechnology | Investor Relations Contact Director/Board Member | |
Foundation for Innovative New Diagnostics
 Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | Chairman Director/Board Member | |
| VERACYTE, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Moleac Pte Ltd.
 Moleac Pte Ltd. Pharmaceuticals: MajorHealth Technology Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore. | Pharmaceuticals: Major | Director/Board Member | |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AFFIMED N.V. | Biotechnology | Chief Tech/Sci/R&D Officer Public Communications Contact | |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member President | |
| NOVARTIS AG | Pharmaceuticals: Major | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
| LONZA GROUP AG | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| MEDIGENE AG | Biotechnology | Director of Finance/CFO Director/Board Member Chief Tech/Sci/R&D Officer | |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Medical Specialties | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
SHS Gesellschaft für Beteiligungsmanagement mbH
 SHS Gesellschaft für Beteiligungsmanagement mbH Investment ManagersFinance SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) is an independent private equity and venture capital firm founded by Bernhard Schirmers and Reinhilde Spatscheck in 1993, and was headquartered in Tübingen, Baden-Württemberg in the southwest of Germany. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Kiel | College/University | Doctorate Degree Doctorate Degree | |
| University of Maryland | College/University | Undergraduate Degree Undergraduate Degree | |
| Université de Montpellier | College/University | Doctorate Degree | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Private Equity Investor Private Equity Investor | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Public Communications Contact Human Resources Officer General Counsel | |
| Georgetown University | College/University | Masters Business Admin Undergraduate Degree | |
Eli Lilly & Co. Ltd.
 Eli Lilly & Co. Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly & Co. Ltd. provides pharmaceutical health care solutions. It provide products for cardiovascular, dermatology, diabetes, endocrine, musculoskeletal, neuroscience, oncology and urology. The company was incorporated on April 9, 1963 and is headquartered in Basingstoke, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Münster | College/University | Undergraduate Degree Doctorate Degree | |
| University of Zurich | College/University | Corporate Officer/Principal Doctorate Degree | |
| Freie Universität Berlin | College/University | Doctorate Degree Graduate Degree | |
| The Johannes Gutenberg University of Mainz | College/University | Doctorate Degree Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Graduate Degree Doctorate Degree | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
| Humboldt-Universität zu Berlin | College/University | Graduate Degree | |
Sanofi-Aventis Recherche et Développement SA
 Sanofi-Aventis Recherche et Développement SA Miscellaneous Commercial ServicesCommercial Services Sanofi-Aventis Recherche et Développement SA is a pharmaceutical company based in Chilly-Mazarin, France. Part of Sanofi, Sanofi-Aventis Recherche et Développement SA is a French company that focuses on delivering medicines and vaccines for millions of people around the world. The private company's R & D teams work closely with patient communities affected by rare hematological disorders to offer them effective and innovative therapeutic care. Find out more about rare hematological disorders in R&D. The company was founded in 1900. Lionel Joël Bascles has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chief Executive Officer | |
| C&F Consulting | Founder | ||
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Chairman Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact | |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Pharmaceuticals: Major | Director/Board Member | |
Carrick Therapeutics UK Ltd.
 Carrick Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Carrick Therapeutics Ltd., Carrick Therapeutics UK Ltd. is a clinical-stage biopharmaceutical company based in Oxford, UK. Carrick Therapeutics translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working in combination with existing oncology drugs to address unmet patient needs. The British company focuses on developing innovative therapies to improve patient outcomes in oncological therapy. The private company's therapies have potential in advanced breast, prostate, and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Timothy R. Pearson has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Chairman | |
| Droia Ventures | Corporate Officer/Principal | ||
Actio Biosciences, Inc.
 Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Pharmaceuticals: Major | Chairman | |
Ananke Therapeutics, Inc.
 Ananke Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ananke Therapeutics, Inc. develops therapeutic medicines for patients. | Pharmaceuticals: Major | Chairman |
Statistics
International
| Germany | 20 |
| United States | 18 |
| Switzerland | 6 |
| France | 5 |
| United Kingdom | 3 |
Sectoral
| Health Technology | 30 |
| Consumer Services | 12 |
| Commercial Services | 5 |
| Finance | 3 |
| Health Services | 2 |
Operational
| Director/Board Member | 171 |
| Corporate Officer/Principal | 120 |
| Independent Dir/Board Member | 61 |
| Chairman | 61 |
| Chief Tech/Sci/R&D Officer | 32 |
Most connected contacts
| Insiders | |
|---|---|
| George Golumbeski | 36 |
| Daniel Camus | 31 |
| Gerald Heinz Möller | 29 |
| Karin Eastham | 29 |
| Wendy Johnson | 23 |
| David Lemus | 22 |
| Frank Morich | 21 |
| Hans Jörg Reinhardt | 20 |
| Geoffrey Nicholas Vernon | 17 |
| Klaus Kühn | 15 |
| Jens Holstein | 14 |
| Sharon Curran | 14 |
| Metin Colpan | 14 |
| Michael Brosnan | 14 |
| Jennifer Herron | 12 |
- Stock Market
- Insiders
- Günter Wellnhofer
- Company connections